Matthew L. Kaplan, Director at Nuvectis Pharma, Inc. (NVCT), bought 3,000 shares at $15.96 ($51K) on 2022-05-12, disclosed to the SEC on 2022-05-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.96 | 1,177 | $19K | 37.1% |
| 2 | $17.47 | 1,823 | $32K | 62.9% |
| Total | $16.88 avg | 3,000 | $51K | 100% |